Clinical Trial Update: OMEGA, Local Ablative Therapy in Oligometastatic NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating local ablative therapy (OMEGA) in oligometastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Azienda Ospedaliera Universitaria Integrata Verona | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: UNKNOWN